AJN, American Journal of Nursing
May 19, 2021
Diane Szulecki
Figure: This month's cover features a colorized magnetic resonance imaging scan of a human brain—a nod to Penn and colleagues' article “Psychedelic-Assisted Therapy,” which presents an overview of a growing field that nurses are positioned to be part of. Photo by Daisy Daisy / Shutterstock.This month's cover features a colorized magnetic resonance imaging scan of a human brain—a nod to Penn and...
May 19, 2021
Evan Lewis-Healey, Ruben Laukkonen, Michiel van Elk
4 citations
preprint
Objective: Recent clinical trials have demonstrated that psilocybin may have strong antidepressant effects, and may be effective in the treatment of depressive disorders when embedded in a psychotherapeutic protocol (psilocybin-assisted psychotherapy; PAP). However, despite promising results, the mechanism(s) that may be responsible for the antidepressant effects of PAP remain contested. Within...
Cureus
May 17, 2021
Sarah Tedesco, Ganeya Gajaram, Shahzad Chida et al.
31 citations
Background: 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as "Molly" or "Ecstasy", is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological profiles remains a controversial subject. Studies have shown the...
Molecules
May 15, 2021
Henry Lowe, Ngeh J. Toyang, Blair Steele et al.
240 citations
The psychedelic effects of some plants and fungi have been known and deliberately exploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric...
Pharmacopsychiatry
May 12, 2021
Gerhard Gründer, Henrik Jungaberle
32 citations
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs that trigger phenomenologically- related experiences like 3,4-methylenedioxymethamphetamine (MDMA) and ketamine, belong to the most promising treatment approaches in contemporary psychiatry. Psychedelic-assisted psychotherapy is not only a new...
ACS Pharmacology & Translational Science
May 4, 2021
James W. Sanders, Josjan Zijlmans
94 citations
The mysticism framework is used to describe psychedelic experiences and explain the effects of psychedelic therapies. We discuss risks and difficulties stemming from the scientific use of a framework associated with supernatural or nonempirical belief systems and encourage researchers to mitigate these risks with a demystified model of the psychedelic state.
Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
May 1, 2021
M J Spriggs, Hannes Kettner, R L Carhart-Harris
Psychedelic therapy is showing promise for a broad range of mental health conditions, indicative of a transdiagnostic action. While the efficacy of symptom-focused treatments for eating disorders (EDs) is limited, improved mental health and psychological wellbeing are thought to contribute to greater treatment outcomes. This study provides the first quantitative exploration of the psychological...
Journal of Psychedelic Studies
April 19, 2021
Cody Gilbert, Mitch Earleywine, Maha N. Mian et al.
3 citations
Abstract Background Ayahuasca's effects on symptoms of depression have generated considerable optimism. Clients frequently report more concern about some symptoms than others, and available treatments alter symptoms differentially. Few studies address the symptom specificity of this psychoactive brew. Aims We examined self-reported effects of ayahuasca on the individual symptoms of depression...
Emerald Expert Briefings
April 9, 2021
Significance: Government authorities, including in the United States, are speeding up licensing for clinical trials of these controlled drugs. Substantial philanthropic funding supports psychedelic medicine and campaigns for regulated use of these drugs, including for treatment of PTSD, chronic depression and addiction. Impacts: Biotechnology companies expect psychedelic therapies to become...
International Review of Psychiatry
April 3, 2021
Catherine Bird, Nadav L. Modlin, James J. H. Rucker
78 citations
This review examines the role of trauma in psychiatric morbidity and analogous psychoneurobiological changes. Trauma is a necessary criterion for Post-Traumatic Stress Disorder (PTSD), however, trauma history is highly correlated with a variety of psychiatric conditions. Some evidence suggests that Major Depressive Disorder (MDD) is the most common psychiatric condition that arises following...